By John Osiecki, Vice President, Medical Affairs for North America, bioMérieux

Imagine the family next door has a college junior who went to an urgent care clinic with a persistent cough and low-grade fever. Like almost 10% of her fellow Alabamians, this young woman is asthmatic. Her doctor had to decide: Is this viral or bacterial? Is it mild or potentially dangerous? Point-of-care respiratory panel testing is performed on the spot. Diagnosis: walking pneumonia and treatment started.

If this person goes into that same clinic next month, her insurance may not cover the same test. She may go home without a diagnosis, potentially turning her walking pneumonia into something much more severe.

This scenario is a possible outcome if proposed health insurance coverage changes take effect April 16. The policy could restrict coverage for infectious disease testing and impact respiratory panels, or groups of tests, that scan for more than five disease-causing organisms at once.

After April 16, some companies providing health insurance to Alabamians will authorize smaller-panel tests for a narrow portion of high-risk patients only. The proposed policy defines high-risk patients in a very restrictive way, more than the accepted CDC definition and excluding patients like the college junior with chronic respiratory diseases like asthma. Access matters for those patients since they are at risk of severe infections caused by a broader range of pathogens in comparison to generally healthy patients.

At first glance, this may sound like a minor change in coverage. However, this decision could fundamentally alter how quickly and accurately patients across Alabama are diagnosed and treated when they are sick, possibly escalating their care to emergency department visits and hospitalization.

To understand what's at stake, it helps to understand what these tests do. Modern respiratory panels detect the genetic material of viruses and bacteria to identify infections quickly from a single patient sample, often during the patient's visit. This is known as point-of-care panel testing, meaning a wide range of results are available while clinical decisions are still being made at the doctor's office.

If the current coverage of panel tests is eliminated, it could have ripple effects. A parent with undiagnosed respiratory infection may spread the disease to other family members. An employee could lose days of work due to lingering illness — especially hard-hitting for hourly workers who aren't paid when they don't work. Or they could decide to go to work anyway, increasing the risk of spreading disease in the community.

The risks are much worse for young children, older adults and people with chronic conditions like asthma, diabetes, cancer, or heart disease. These groups are more vulnerable to respiratory infections and more likely to experience severe outcomes if treatment is delayed.

Doctors could feel restricted in their ability to make timely, appropriate decisions when they initially evaluate patients at their office or at urgent care clinics. This could result in more patients going to hospital emergency rooms, spreading infectious diseases and taking resources away from true emergencies that can only be treated at hospitals.

Evidence-based testing delivers documented improvements in quality of care and outcomes through tools providers already use effectively today. Limiting access to respiratory panels would make diagnosis slower, less certain and less effective.

To learn more about the proposed policy and share your opinion by April 15, you can review the draft policy by visiting the medical policies website here and submit comments through this portal.